212 results about "Helicobacter pylori bacteria" patented technology

A method for treatment of bacterial infections with rifalazil administered once-weekly or twice-weekly. A method for treatment of tuberculosis caused by Mycobacterium tuberculosis, infections caused by Mycobacterium avium complex, infections caused by Chlamydia pneumoniae and infections caused by Helicobacter pylori by administering to a patient suffering from the bacterial infection 1-100 mg of rifalazil once or twice a week. In this dose regimen, the treatment is fast, efficacious and eliminates undesirable secondary symptoms observed with daily doses of 1-50 mg of rifalazil.

The invention provides lactobacillus plantarum capable of resisting helicobacter pylori infection and application of the lactobacillus plantarum. The lactobacillus plantarum capable of resisting helicobacter pylori infection is named as lactobacillus plantarum Lp05 and is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.23547, and the preservation date is October 9, 2021. The invention also provides a culture method of the lactobacillus plantarum for resisting helicobacter pylori infection and a product for inhibiting helicobacter pylori infection. The lactobacillus plantarum for resisting helicobacter pylori infection is good in gastric acid resistance, proliferation of helicobacter pylori is inhibited, the adhesion effect of helicobacter pylori on gastric epithelial cells is reduced, and conditions are created for eradicating helicobacter pylori. The product for inhibiting helicobacter pylori infection does not cause adverse reaction and drug resistance of pathogenic bacteria, and is high in application value.

The invention discloses a recombinant helicobacter pylori protein vaccine and a preparation method thereof. The active ingredient recombinant fusion protein of the vaccine consists of recombinant LTAl-Ureal protein and LTB protein, the amino acid sequence of the recombinant LTAl-Ureal protein is shown as Seq ID No.1, the amino acid sequence of the LTB protein is shown as Seq ID No.2. Epitope-containing gene segments of Hp urease A subunit is inserted in an LTA subunit-encoded gene, a toxic part-containing segment is replaced to prepare a recombinant plasmid so as to express and obtain recombinant fusion protein polymer as a vaccine antigen, the fusion antigen and LTB protein pentamer are combined to form a hexamer structure, so that not only can the structure basis and activity of an LT mucosa adjuvant be remained, but also the toxicity can be removed, the immune response of organism muscosa can be effectively induced through immunity of mucosa path, to generate specific IgA antibody. The recombinant helicobacter pylori protein vaccine provides a vaccine manner for preventing and treating infection of helicobacter pylori.

Chromogenic 3-Indoxyl choline phosphate compounds of formula (I):wherein R is selected from the group consisting of hydrogen and C1-4 alkyl, such as methyl, ethyl, propyl and butyl while R<1>, R<2>, R<3>, and R<4 >are independently selected from the group consisting of hydrogen, halogen, cyano, nitro, carboxy, amino, amino substituted with one or two C1-4 alkyl groups, aminomethyl, hydroxy, C1-4 alkoxy, carboxyalkyl, and sulphonyl. These compounds are capable of being cleaved by lecithinase C leading to products which are calorimetrically detectable. The invention provides safe and sensitive detection of potentially pathogenic bacterial activity of such microbes as Clostridium perfringens, Bacillus cereus, Bacillus anthracis, Pseudomonas aeruginosa, Listeria monocytogenes, Heliobacter pylori, Legionella pneumophila, and others in material which may contain such activity typically including physiological samples, goods for consumption, such as food and beverages, and any other potentially infected objects or articles.

The invention discloses an urea enzyme epitope fuse peptiolipid plastid vaccine to against pylorus bolt bacteria infection, which is characterized by the following: choosing fuse peptide of pylorus bolt bacteria urea enzyme B subunit and stick film adjuvant cholera morbus toxin B subunit as immunogen; coating the immunogen with liposome; producing the liposome vaccine. This liposome vaccine can evoke organism to generate special immune response and inhibit planting of pylorus bolt bacteria in stomach.

The invention provides a method of screening a bacterial strain capable of inhibiting helicobacter pylori. The method includes a way that qualitative and quantitative assessment can be directly conducted on screened bacterial strains if the screened bacterial strains can inhibit or eliminate the colonization of the helicobacter pylori on gastric mucosal cells by utilizing DNA fluorescent labels and flow cytometry. According to the invention, the following points are considered when conducting screening model tests in vitro: (1) viability in an extremely acidic stomach environment; (2) inhibition ability of the bacterial strains itself or metabolites of the bacterial strains to HP reproduction in vitro; and (3) ability of inhibiting or relieving the colonization of the helicobacter pylori strains on gastric mucosa. According to the invention, developing the method of directly assessing in vitro if the HP colonization can be inhibited is of great significance to the practical applicationof the bacterial strain provided by the invention. According to the invention, lactobacillus acidophilus LA-10A capable of inhibiting the helicobacter pylori is screened out. According to a test, thelactobacillus acidophilus LA-10A can relieve or prevent the helicobacter pylori infection. The lactobacillus acidophilus LA-10A can be used to prepare functional food or pharmaceutical compositions.

The invention provides a composition for resisting helicobacter pylori and an application of the composition. Each 100g of the composition comprises the following active components according to the content: 5-20g of inactivated lactobacillus reuteri, 0.1-1g of inactivated lactobacillus paracasei, 1.5-25g of bifidobacterium animalis viable bacteria, 1.2-20g of lactobacillus rhamnosus, 5-10g of hippophae rhamnoides fruit powder, 0.1-1g of a broccoli seed aqueous extract, 20-30g of fructo-oligosaccharide and 10-70g of lacitiol. According to the composition, the inactivated lactobacillus reuteri,the inactivated lactobacillus paracasei, the hippophae rhamnoides fruit powder, the broccoli seed aqueous extract, the fructo-oligosaccharide and the lacitiol are prepared into a specific compositionformula together, and the formula not only can well prevent and treat bacterial infection of gastrointestinal tracts and bacterial infection of oral cavities, particularly concurrently has better mouth feel flavor, and is green and healthy due to no addition of seasonings of essence and the like.

The invention discloses quantitative determination and drug allergy determination kits for helicobacter pylori viable bacteria and a determination method. The method adopts viable helicobacter pylori as a sample to be detected; the property that the viable helicobacter pylori can generate urease is used for rapidly and accurately reading the quantity of the helicobacter pylori by a helicobacter pylori colony counting standard method (CFU / ml, namely the bacterium individual quantity in each ml of bacterium liquid and a colony quantity standard curve); the detection result is accurate and sensitive and has high reliability; the counting difficulty of existing helicobacter pylori clinic microbiological identification, caused by difficult culture and complicated operation, is solved; the drug allergy determination kit and a preparation method, which are expanded by the invention, can be used for carrying out various drug allergy tests at the same time; clinicians can rapidly and conveniently screen suitable anti-helicobacter pylori medicines so that the time and the labor are saved and the cost is saved, so as to provide a beneficial technical solution for clinical scientific treatment.

A novel multiplex polymerase chain reaction assay for detecting a bacteria (e.g. Helicobacter pylori) in a specimen uses multiple oligonucleotide primer pairs based on the sequences of multiple loci of the bacteria. In one application, up to five loci in the genomic DNA sequences of Helicobacter pylori were amplified. Two fragments of H. pylori were amplified from each locus, wherein a second fragment was an internal fragment of the first fragment.

The invention discloses traditional Chinese medicinal compound collutory and a preparation method thereof. The collutory is prepared from the following raw materials in percentage by weight: 5-10 parts of fulvic acid, 3-7 percent of cortex meliae, 3-7 percent of semen litchi, and the balance of auxiliary materials. Compared with existing collutory, the traditional Chinese medicinal compound collutory can effectively inhibit growth of dental plaque, is excellent in effect proved by experiments, and cannot generate strong inhibition to resident bacteria in the oral cavity, is advantageous to keep ecological balance of bacteria in the oral cavity; the collutory disclosed by the invention can effectively reduce the side effect of medicinal collutory, has an excellent specific inhibition to helicobacter pylori by adopting cortex meliae, semen litchi and fulvic acid as main medicinal effective components of the collutory, is advantageous to keep microecological balance of the oral cavity, and reduces the side effect of medicinal collutory.

The immunological microsphere method of detecting pyloric helicobacterium in stool sample includes labeling microsphere to form immunological microsphere; suspending the tested stool sample containing pyloric helicobacterium in buffering liquid; mixing the immunological microsphere and the sample buffering liquid or mixing pyloric helicobacterium resisting antibody with the buffering liquid before adding pyloric helicobacterium resisting antigen labeled microsphere; and detecting pyloric helicobacterium in the stool sample. The method has the advantages of low cost, fast and convenient operation and reliable result.

The invention discloses lactobacillus crispatus capable of preventing and / or treating helicobacter pylori infection, and belongs to the technical field of microorganisms and medicines. The invention provides the lactobacillus crispatus CCFM1118. The lactobacillus crispatus CCFM1118 can inhibit helicobacter pylori, and is specifically characterized in that: (1) the size of an inhibition zone of a lactobacillus crispatus CCFM1118 supernatant on helicobacter pylori can reach 13.14 mm; and (2) the lactobacillus crispatus CCFM1118 can significantly reduce the adhesion of helicobacter pylori to AGScells; therefore, the lactobacillus crispatus CCFM1118 has a huge application prospect in the aspects of inhibiting helicobacter pylori (not aiming at the diagnosis and treatment of diseases) and preparing a helicobacter pylori inhibitor.

The invention relates to Chinese medicinal herbal toothpaste comprising an anti-helicobacter pylori Chinese medicinal herbal active composition; the Chinese medicinal herbal toothpaste comprises a paste base and the anti-helicobacter pylori Chinese medicinal herbal active composition extracted by a supercritical CO2; wherein, the percentage of the Chinese medicinal herbal active composition accounted for the total weight of the Chinese medicinal herbal toothpaste is 0.5%-10%; and the remaining weight is the paste base. By adding the Chinese medicinal herbal active matter obtained by the technology of the supercritical CO2 extraction and separation into the toothpaste, the invention well solves the disadvantages of traditional extractive technique of the anti-helicobacter pylori Chinese medicinal herbal active composition, and the anti-helicobacter pylori Chinese medicinal herbal active composition with the definite composition is obtained; the purity of the anti-helicobacter pylori Chinese medicinal herbal active composition is very high, thereby being suitable for using as the medicated additive of the toothpaste. By adopting the invention, the Chinese medicinal herbal health care toothpaste which has high content of the anti-helicobacter pylori Chinese medicinal herbal active composition and good effect of inhibiting and killing the helicobacter pylori can be reliably obtained.

The invention discloses an oral care product containing curcumin and having anti-Hp (helicobacter pylori) efficacy. The oral care product is characterized by containing the curcumin. The invention provides a kind of traditional Chinese medicine oral care products, a medicine extracting method is simple, dosage and ingredients are stable, and the products can go deep into an oral cavity directly. The oral care product cannot cause internal environment disturbance of the oral cavity when used for a long time, has no side effects, not only has similar functions including halitosis removal, oral ulcer treatment, resistance to common pathogenic bacteria in the oral cavity and inflammation diminishing to the conventional oral care products such as Chinese herbal medicine health care toothpaste and the like, but also has the functions of Hp killing and effective prevention of oral transmission of Hp. Natural curcumin is applied to the oral care products such as the toothpaste and the like, the oxidation resistance of the products is improved, and the shelf life is prolonged.

The invention relates to a detection reagent card for typing test of helicobacter pylori. The detection reagent card comprises a sample pad, a quantum pad, a nitrocellulose membrane, absorbent paper and a lining plate, wherein a quantum dot microsphere labeled antigen complex is coated on the quantum pad; the antigen complex comprises a Urease antigen, a CagA antigen, a VacA antigen and rate IgG;a first detection line, a second detection line, a third detection line and a quality control line are arranged on the nitrocellulose membrane; the VacA antigen is coated on the first detection line;the CagA antigen is coated on the second detection line; the Urease antigen is coated on the third detection line; and the goat anti-rat IgG is coated on the quality control line. The detection reagent card for typing test of helicobacter pylori provided by the invention is capable of rapidly and accurately obtaining the results, the infection type of the helicobacter pylori can be judged according to the detection result, and auxiliary diagnosis is further provided for clinical related diseases.

The invention discloses composition with a function of clearing peculiar smell in an oral cavity. The composition is prepared from raw materials in parts by weight as follows: 1-20 parts of common lophatherum herbs, 10-50 parts of purslane, 10-40 parts of chrysanthemums, 20-40 parts of honeysuckles, 1-20 parts of lotus leaves and 1-30 parts of mint. The composition is prepared from six medicinal and edible Chinese herbs. A pharmacological experiment can inhibit multiple anaerobic bacteria and helicobacter pylori causing the peculiar smell of the oral cavity, and a clinical controlled study result further proves that the composition can relieve the subjective symptom of the patients with peculiar smell in the oral cavity.

The present invention provides a pharmaceutical composition and a food product for inhibiting gastritis induced by gastric Helicobacter pylori, comprising Lactobacillus selected from a group composed of Lactobacillus rhamnosus GM-020 (also known as GMNL-74) with deposited number CCTCC M203098; Lactobacillus acidophilus GMNL-185 with deposited number CCTCC M2017764; and Lactobacillus plantarum GMNL-662 with deposited number CCTCC M2016571; and any two of the above bacteria.

A compound of the formula (I):wherein R1 represents an amino group which may be substituted; R2 represents a carboxy group which may be esterified or amidated; R3, R4, R5 and R6 each represent a hydroxy group which may be protected; Q represents an aryl group which may be substituted; or a salt thereof is disclosed. The compound (I) possesses ant-Helicobacter pylori activity, and is useful in the prevention or treatment of various diseases associated with Helicobacter bacteria, such as duodenal ulcer, gastric ulcer, chronic gastritis and cancer of the stomach.

The invention relates to a helicobacter pylori NapA protein expressed recombinant vector, a recombinant strain and preparation methods and application thereof and belongs to the technical field of biology. According to the helicobacter pylori NapA protein expressed recombinant vector disclosed by the invention, when recombinant plasmid pNZ8110 delta sp-napA is constructed, a secretion signal sequence in the pNZ8110 is removed; thus, NapA molecules expressed by the recombinant vector disclosed by the invention does not carry secretion signal peptide, molecular weight is 15KD, adverse effects toNapA biological activity are avoided, and the adverse effects are caused by the fact that signal peptide cannot be excised in thalli when the recombinant strain fails in secretion expression protein.The helicobacter pylori NapA expressed lactococcus lactis recombinant strain disclosed by the invention not only can be applied to preparing immune adjusting drugs, but also can be applied to producing health care food with an immune adjusting effect; the helicobacter pylori NapA expressed lactococcus lactis recombinant strain also has important significance in preventing and treating diseases offood allergy, immunosuppression, tumor and the like and can generate considerable social and economic benefits.

The invention provides a method for guiding helicobacter pylori to eradicate drug use based on a PGM high throughput sequencing technology, and mainly aims to realize detection of helicobacter pylori on antibiotic drug resistance and host drug metabolic enzyme types. The method mainly comprises the steps of designing a specific primer for covering VacA, 23SrRNA, gyrA, CYP2C19*2 and CYP2C19*3 gene to-be-detected regions to form a Primer Pool; extracting host and helicobacter pylori genome to perform amplification; performing PGM library preparation, purification, quantifying and sequencing; and working out drug resistance proportion and drug metabolic enzyme types. By adoption of multiple PCR technologies, synchronous amplification of multiple sites can be realized; and by combination with PGM sequencing, guiding to clinical detection and eradiation of the helicobacter pylori can be facilitated.

The invention discloses an MLH fusion antibacterial peptide, a preparation method and application thereof. Housefly antibacterial peptide, LL-37 and helicobacter pylori peptide are adopted as the parent peptide, a bioinformatics method is utilized for analysis to obtain an amino acid sequence of MLH, and a gene fragment of the hybrid gene MLH is encoded according to the E.coli codon preference. SOE-PCR technology is employed to synthesize a required target gene, the target gene is connected to the expression vector pET-32a(+), and the obtained recombinant expression vector is transferred into an escherichia coli expression strain to construct the recombinant genetic engineering strain pET-32a-MLH / BL21(DE3), IPTG induced protein fusion expression is carried out, and finally bacteriostatic activity identification is conducted on the obtained fusion expressed hybrid peptide, and the result indicates that the fusion expressed hybrid peptide has significant bacteriostatic effect on staphylococcus aureus and bacillus subtilis.

The invention discloses an intramolecular adjuvant-containing recombinant gene for preventing and treating helicobacter pylori, protein and a biological product. the multi-target recombinant gene comprises a multi-target fusion polypeptide having an amino acid sequence shown in a SEQ ID NO:2, a multi-target recombinant gene for coding the multi-target fusion polypeptide having the nucleotide sequence shown in a SEQ ID NO:2, and invention also has an application of a specific antibody of the above multi-target recombinant gene or the above multi-target fusion polypeptide or the multi-target fusion polypeptide as the biological product for preventing and treating helicobacter pylori infection. According to the invention, an intramolecular adjuvant CTB for removing signal peptide is added at N segment of a recombinant helicobacter pylori multi-target fusion polypeptide (rIB), so that prevention and treatment effect for the helicobacter pylori infection can be increased.

The invention belongs to the technical field of microorganisms, and provides lactobacillus rhamnosus LR863 and lactobacillus rhamnosus LR519 for synergistically inhibiting helicobacter pylori and application of the lactobacillus rhamnosus LR863 and the lactobacillus rhamnosus LR519. The lactobacillus rhamnosus LR863 and the lactobacillus rhamnosus LR519 are included; mixed probiotics are used for preparing a food for inhibiting the helicobacter pylori in the oral cavity and the stomach and improving the intestinal tract; the food comprises a component A and a component B; the component A is mixed probiotics composed of the lactobacillus rhamnosus LR863 and the lactobacillus rhamnosus LR519 in the mass ratio of (1-2): 1; the component B comprises the following components in parts by weight of 15 parts of hericium erinaceus powder, 3 parts of galacto-oligosaccharide, 15 parts of poria cocos powder, 10 parts of spirulina and 20 parts of sea-buckthorn powder; the food further comprises a component C; and the component C is one or more of bifidobacterium, lactobacillus acidophilus and lactobacillus plantarum. By means of the technical scheme, the problem that in the prior art, a composition for inhibiting the helicobacter pylori has a relatively single inhibiting effect on the helicobacter pylori is solved.

The invention discloses mouthwash containing a plant formula and a preparation method thereof. The mouthwash comprises the following components in parts by mass: 0.33-40 parts of active ingredients, 1-15 parts of flavoring agent and 40-95 parts of water, wherein the active ingredients include 0.1-8 parts of propolis, 0.01-5 parts of casein phosphopeptide, 0.1-0.5 part of broadleaf holly leaf extract, 0.01-5 parts of pepper extract, 0.01-0.3 part of garlic extract, 0.05-5 parts of tea polyphenol and 0.05-5 parts of clove extract all by mass. The components are combined in the mouthwash; due to the synergistic effect of the components, the mouthwash shows relatively good antibacterial effect against bacteria and fungi and particularly helicobacter pylori and other common pathogenic bacteria in mouth, can effectively resist and inhibit bacteria and effectively inhibit and eliminate dental plaque and can be used for effectively treating the mouth problems such as halitosis and oral ulcer; and the mouthwash does not cause disorder of microbial environment in the mouth after long-time use.

The invention discloses an oral care product containing propolis alcohol extract and having anti-Hp (helicobacter pylori) efficacy. The oral care product is characterized by containing the propolis alcohol extract. The invention provides a kind of traditional Chinese medicine oral care products, a medicine extracting method is simple, dosage and ingredients are stable, and the products can go deep into an oral cavity directly. The oral care product cannot cause internal environment disturbance of the oral cavity when used for a long time and has no side effects. Propolis contains a large quantity of flavonoid, aromatic acid, fatty acid and terpene compounds and has a broad-spectrum antibacterial function. The oral care product not only has similar functions including halitosis removal, oral ulcer treatment, resistance to common pathogenic bacteria in the oral cavity and inflammation diminishing to the conventional oral care products such as Chinese herbal medicine health care toothpaste and the like, but also has the functions of Hp killing and effective prevention of oral transmission of Hp. Natural propolis is applied to the oral care products such as the toothpaste and the like, the oxidation resistance of the products is improved, and the shelf life is prolonged.

The invention relates to the technical field of microorganisms, in particular to lactobacillus reuteri SF-L-25 with a helicobacter pylori inhibiting function and application thereof. The lactobacillusreuteri SF-L-25 is preserved in the China General Microbiological Culture Collection Center on October 26, 2020, and the preservation number of the lactobacillus reuteri SF-L-25 is CGMCC No. 20956; and the lactobacillus reuteri is named as lactobacillus reuteri in a classified manner. The preservation address is No.3, Yard 1, West Beichen Road, Chaoyang District, Beijing; the lactobacillus reuteri SF-L-25 is separated and screened from gastric mucus of a healthy human body, is high in safety, has relatively strong stability, inhibits helicobacter pylori growth and urease activity, the problems of gastrointestinal dysfunction, gastrointestinal dysbacteriosis and other adverse reactions caused by long-term unreasonable use of antibiotics in the process of preventing and treating helicobacter pylori infection are effectively solved; meanwhile, the lactobacillus reuteri SF-L-25 has remarkable functional characteristics so that the lactobacillus reuteri SF-L-25 has wide application value in probiotic solid beverages.

The invention relates to an application of bacillus subtilis in antagonism helicobacter pylori, wherein substances capable of restraining the growth of helicobacter pylori can be generated when the shake cultivation is performed on the bacillus subtilis for 9 hours at 37 DEG C and at a speed of 180 rpm (revolutions per minute) in a nutrient broth liquid culture medium, thereby efficiently restraining the growth of the helicobacter pylori; when the bacillus subtilis is cultivated for 18 hours, the antibiotic ability is maximum; and antagonistic proteins are acquired by purifying the substances, thereby preparing a preparation for treating gastrointestinal tract diseases. The invention has the following technical effects: the bacillus subtilis from probiotics has a function of maintaining the micro ecological balance of an intestinal tract; the bacillus subtilis culture has stronger antagonism to the helicobacter pylori; and compared with the antibiotic treatment method used for conventionally treating the helicobacter pylori, the bacillus subtilis can be used for overcoming the defects that the side effect by using antibiotic treatment method is strong and the symptoms are easily reappeared after the disease is treated, and the like.

The invention relates to the field of traditional Chinese medicine, in particular to a traditional Chinese medicine composition for inhibiting helicobacter pylori and a preparation method thereof. Thetraditional Chinese medicine composition comprises the following components in parts by weight: 5-15 parts of fructus canarii, 0-6 parts of flos sophorae immaturus and 0-5 parts of radix glycyrrhizae. The traditional Chinese medicine composition for inhibiting the helicobacter pylori disclosed by the invention has the action characteristics of multiple components, multiple ways and multiple targets, and a traditional Chinese medicine therapy method is low in drug resistance occurrence rate, few in adverse reactions and good in patient medication compliance. The composition is reasonable in compatibility, has a strong inhibiting effect on helicobacter pylori antibiotic-sensitive strains and drug-resistant strains, prevents bitter cold from injuring the stomach, and is suitable for helicobacter pylori infected people, and the use of antibiotics can be reduced by applying traditional Chinese medicines, so that the drug resistance rate of the helicobacter pylori is reduced.